177 related articles for article (PubMed ID: 34114372)
1. A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.
Szeglin BC; Wu C; Marco MR; Park HS; Zhang Z; Zhang B; Garcia-Aguilar J; Beauchamp RD; Chen XS; Smith JJ
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1423. PubMed ID: 34114372
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer.
Lampropoulos P; Zizi-Sermpetzoglou A; Rizos S; Kostakis A; Nikiteas N; Papavassiliou AG
Tumour Biol; 2012 Aug; 33(4):1005-14. PubMed ID: 22278155
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
4. Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8-CXCR2 Axis.
Ogawa R; Yamamoto T; Hirai H; Hanada K; Kiyasu Y; Nishikawa G; Mizuno R; Inamoto S; Itatani Y; Sakai Y; Kawada K
Clin Cancer Res; 2019 May; 25(9):2887-2899. PubMed ID: 30705034
[TBL] [Abstract][Full Text] [Related]
5. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin.
Freeman TJ; Smith JJ; Chen X; Washington MK; Roland JT; Means AL; Eschrich SA; Yeatman TJ; Deane NG; Beauchamp RD
Gastroenterology; 2012 Mar; 142(3):562-571.e2. PubMed ID: 22115830
[TBL] [Abstract][Full Text] [Related]
6. Preliminary Study of the Role F-Box Protein 32 (FBXO32) in Colorectal Neoplasms Through the Transforming Growth Factor beta (TGF-β)/Smad4 Signalling Pathway.
Yuan X; Zhang Z; Jiang K; Wang X; Li Y
Med Sci Monit; 2018 Feb; 24():1080-1088. PubMed ID: 29465067
[TBL] [Abstract][Full Text] [Related]
7. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
Wasserman I; Lee LH; Ogino S; Marco MR; Wu C; Chen X; Datta J; Sadot E; Szeglin B; Guillem JG; Paty PB; Weiser MR; Nash GM; Saltz L; Barlas A; Manova-Todorova K; Uppada SPB; Elghouayel AE; Ntiamoah P; Glickman JN; Hamada T; Kosumi K; Inamura K; Chan AT; Nishihara R; Cercek A; Ganesh K; Kemeny NE; Dhawan P; Yaeger R; Sawyers CL; Garcia-Aguilar J; Giannakis M; Shia J; Smith JJ
Clin Cancer Res; 2019 Mar; 25(6):1948-1956. PubMed ID: 30587545
[TBL] [Abstract][Full Text] [Related]
8. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
[TBL] [Abstract][Full Text] [Related]
9. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK.
Voorneveld PW; Kodach LL; Jacobs RJ; Liv N; Zonnevylle AC; Hoogenboom JP; Biemond I; Verspaget HW; Hommes DW; de Rooij K; van Noesel CJ; Morreau H; van Wezel T; Offerhaus GJ; van den Brink GR; Peppelenbosch MP; Ten Dijke P; Hardwick JC
Gastroenterology; 2014 Jul; 147(1):196-208.e13. PubMed ID: 24704720
[TBL] [Abstract][Full Text] [Related]
10. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
[TBL] [Abstract][Full Text] [Related]
11. SMAD4 alteration associates with invasive-front pathological markers and poor prognosis in colorectal cancer.
Oyanagi H; Shimada Y; Nagahashi M; Ichikawa H; Tajima Y; Abe K; Nakano M; Kameyama H; Takii Y; Kawasaki T; Homma KI; Ling Y; Okuda S; Takabe K; Wakai T
Histopathology; 2019 May; 74(6):873-882. PubMed ID: 30636020
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
13. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
Itatani Y; Kawada K; Fujishita T; Kakizaki F; Hirai H; Matsumoto T; Iwamoto M; Inamoto S; Hatano E; Hasegawa S; Maekawa T; Uemoto S; Sakai Y; Taketo MM
Gastroenterology; 2013 Nov; 145(5):1064-1075.e11. PubMed ID: 23891973
[TBL] [Abstract][Full Text] [Related]
14. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
[TBL] [Abstract][Full Text] [Related]
15. Antimetastatic role of Smad4 signaling in colorectal cancer.
Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK
Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744
[TBL] [Abstract][Full Text] [Related]
16. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.
Voorneveld PW; Kodach LL; Jacobs RJ; van Noesel CJ; Peppelenbosch MP; Korkmaz KS; Molendijk I; Dekker E; Morreau H; van Pelt GW; Tollenaar RA; Mesker W; Hawinkels LJ; Paauwe M; Verspaget HW; Geraets DT; Hommes DW; Offerhaus GJ; van den Brink GR; Ten Dijke P; Hardwick JC
Br J Cancer; 2015 Jan; 112(1):122-30. PubMed ID: 25393365
[TBL] [Abstract][Full Text] [Related]
17. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
18. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
[TBL] [Abstract][Full Text] [Related]
19. Role of TGF-beta1, its receptor TGFbetaRII, and Smad proteins in the progression of colorectal cancer.
Gulubova M; Manolova I; Ananiev J; Julianov A; Yovchev Y; Peeva K
Int J Colorectal Dis; 2010 May; 25(5):591-9. PubMed ID: 20165854
[TBL] [Abstract][Full Text] [Related]
20. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
